0001593968-24-000562.txt : 20240408
0001593968-24-000562.hdr.sgml : 20240408
20240408172735
ACCESSION NUMBER: 0001593968-24-000562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240404
FILED AS OF DATE: 20240408
DATE AS OF CHANGE: 20240408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Parker Craig C
CENTRAL INDEX KEY: 0001526064
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39635
FILM NUMBER: 24830559
MAIL ADDRESS:
STREET 1: 21 BEVERLY TERRACE
CITY: MILL VALLEY
STATE: CA
ZIP: 94941
FORMER NAME:
FORMER CONFORMED NAME: Parker Craig C.
DATE OF NAME CHANGE: 20150730
FORMER NAME:
FORMER CONFORMED NAME: Parker Craig C
DATE OF NAME CHANGE: 20110718
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Surrozen, Inc./DE
CENTRAL INDEX KEY: 0001824893
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 301374889
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-475-2820
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Consonance-HFW Acquisition Corp.
DATE OF NAME CHANGE: 20200915
4
1
primary_01.xml
PRIMARY DOCUMENT
X0508
4
2024-04-04
0001824893
Surrozen, Inc./DE
SRZN
0001526064
Parker Craig C
C/O SURROZEN, INC.
171 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
Chief Executive Officer
false
Common Stock
2024-04-04
4
P
false
1474
A
1474
D
Series A Common Stock Warrant (right to buy)
16.96
2024-04-04
4
P
false
1474
A
2024-04-04
2029-04-04
Common Stock
1474
1474
D
Series B Common Stock Warrant (right to buy)
15.71
2024-04-04
4
P
false
1603
A
2024-04-04
Common Stock
1603
1603
D
Series C Common Stock Warrant (right to buy)
16
2024-04-04
4
P
false
5712
A
Common Stock
5712
5712
D
Series D Common Stock Warrant (right to buy)
16
2024-04-04
4
P
false
5712
A
Common Stock
5712
5712
D
On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.
The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.
The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).
The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).
/s/Charles Williams, Attorney-in-Fact for Craig C Parker
2024-04-08